Professional Documents
Culture Documents
BACKGROUND: Although the place of death has a great influence on the quality of death and dying for cancer patients, whether the
survival time differs according to the place of death is unclear. The primary aim of this study was to explore potential differences in
the survival time of cancer patients dying at home or in a hospital. METHODS: This multicenter, prospective cohort study was con-
ducted in Japan from September 2012 through April 2014 and involved 58 specialist palliative care services. RESULTS: Among the
2426 patients recruited, 2069 patients were analyzed for this study: 1582 receiving hospital-based palliative care and 487 receiving
home-based palliative care. A total of 1607 patients actually died in a hospital, and 462 patients died at home. The survival of patients
who died at home was significantly longer than the survival of patients who died in a hospital in the days’ prognosis group (estimated
median survival time, 13 days [95% confidence interval (CI), 10.3-15.7 days] vs 9 days [95% CI, 8.0-10.0 days]; P 5 .006) and in the
weeks’ prognosis group (36 days [95% CI, 29.9-42.1 days] vs 29 days [95% CI, 26.5-31.5 days]; P 5 .007) as defined by Prognosis in
Palliative Care Study predictor model A. No significant difference was identified in the months’ prognosis group. Cox proportional
Corresponding author: Jun Hamano, MD, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8575,
Japan; Fax: (011) 81-298-53-3189; junhamano@md.tsukuba.ac.jp
1
Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan; 2Department of Palliative Medicine, Kobe University Graduate School of
Medicine, Kobe, Japan; 3 Department of Palliative Medicine, Graduate School of Medicine, Osaka University, Suita, Japan; 4Department of Palliative Medicine, Shi-
zuoka Saiseikai General Hospital, Suruga, Japan; 5Tsukuba Medical Center Foundation, Tsukuba, Japan; 6Palliative Care Department, Okayama Saiseikai General
Hospital, Okayama City, Japan; 7Matsue City Hospital, Matsue City, Japan; 8Department of Palliative Care Unit, Japan Community Health Care Organization (JCHO)
Tokyo Shinjuku Medical Center, Tokyo, Japan; 9Aozora Clinic, Matsudo City, Japan; 10Department of Palliative Medicine, Wakayama Medical University Hospital
Oncology Center, Wakayama, Japan; 11 Department of Palliative Care, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Ja-
pan; 12 Gratia Hospital Hospice, Mino, Japan; 13 Department of Palliative Medicine, Graduate School of Medicine, Tohoku University, Sendai, Japan; 14Kawasaki
Comprehensive Care Center, Kawasaki Municipal Ida Hospital, Kawasaki, Japan; 15Palliative Care Team, Cancer Institute Hospital, Tokyo, Japan; 16 Department of
Palliative Care, Aichi Cancer Center Hospital, Nagoya, Japan; 17 Shinjo Clinic, Kobe Shinjo Clinic, Kobe, Japan; 18Iryouhoujinn Takumikai Osaka Kita Homecare Clinic,
Osaka City, Japan; 19 Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan; 20Palliative and Supportive Care
Division, Seirei Mikatahara General Hospital, Hamamatsu-Shi, Japan
This study was performed by the Japan Prognostic Assessment Tools Validation study group. The participating investigators (and study sites) were as follows:
Satoshi Inoue, MD (Seirei Hospice, Seirei Mikatahara General Hospital); Masayuki Ikenaga, MD (Hospice Children’s Hospice Hospital, Yodogawa Christian Hospital);
Yoshihisa Matsumoto, MD, PhD (Department of Palliative Medicine, National Cancer Center Hospital East); Mika Baba, MD (Department of Palliative Care, Saito
Yukoukai Hospital); Ryuichi Sekine, MD (Department of Pain and Palliative Care, Kameda Medical Center); Takashi Yamaguchi, MD, PhD (Department of Palliative
Medicine, Kobe University Graduate School of Medicine); Takeshi Hirohashi, MD (Department of Palliative Care, Mitui Memorial Hospital); Tsukasa Tajima, MD (Depart-
ment of Palliative Medicine, Tohoku University Hospital); Ryohei Tatara, MD (Osaka City General Hospital, Department of Palliative Medicine); Hiroaki Watanabe, MD
(Komaki City Hospital); Hiroyuki Otani, MD (Department of Palliative Care Team and Palliative and Supportive Care, National Kyushu Cancer Center); Chizuko Taki-
gawa, MD (Department of Palliative Care, KKR Sapporo Medical Center); Yoshinobu Matsuda, MD (Department of Psychosomatic Medicine, National Hospital); Hiroka
Nagaoka, MD (Department of Medical Social Service Center for Palliative, University of Tsukuba); Masanori Mori, MD (Seirei Hamamatsu General Hospital); Yo Tei, MD
(Seirei Hospice, Seirei Mikatahara General Hospital); Shuji Hiramoto, MD (Department of Oncology, Mitsubishi Kyoto Hospital); Akihiko Suga, MD (Department of Palli-
ative Medicine, Shizuoka Saiseikai General Hospital); Takayuki Hisanaga, MD (Tsukuba Medical Center Foundation); Tatsuhiko Ishihara, MD (Palliative Care Depart-
ment, Okayama Saiseikai General Hospital); Tomoyuki Iwashita, MD (Matsue City Hospital); Keisuke Kaneishi, MD, PhD (Department of Palliative Care Unit, Japan
Community Health Care Organization (JCHO) Tokyo Shinjuku Medical Center); Shohei Kawagoe, MD (Aozora Clinic); Toshiyuki Kuriyama, MD, PhD (Department of
Palliative Medicine, Wakayama Medical University Hospital Oncology Center); Takashi Maeda, MD (Department of Palliative Care, Tokyo Metropolitan Cancer and In-
fectious Disease Center, Komagome Hospital); Ichiro Mori, MD (Gratia Hospital Hospice); Nobuhisa Nakajima, MD, PhD (Department of Palliative Medicine, Graduate
School of Medicine, Tohoku University); Tomohiro Nishi, MD (Kawasaki Comprehensive Care Center, Kawasaki Municipal Ida Hospital); Hiroki Sakurai, MD (Depart-
ment of Palliative Care, St. Luke’s International Hospital); Satofumi Shimoyama, MD, PhD (Department of Palliative Care, Aichi Cancer Center Hospital); Takuya Shinjo,
MD (Shinjo Clinic); Hiroto Shirayama, MD (Iryouhoujinn Takumikai Osaka Kita Homecare Clinic); Takeshi Yamada, MD, PhD (Department of Gastrointestinal and
Hepato-Biliary-Pancreatic Surgery, Nippon Medical School); Shigeki Ono, MD (Division of Palliative Medicine, Shizuoka Cancer Center Hospital); Taketoshi Ozawa, MD,
PhD (Megumi Zaitaku Clinic); Ryo Yamamoto, MD (Department of Palliative Medicine, Saku Central Hospital Advanced Care Center); Naoki Yamamoto, MD, PhD
(Department of Primary Care Service, Shinsei Hospital); Hideki Shishido, MD (Shishido Internal Medicine Clinic); Mie Shimizu, MD (Saiseikai Matsusaka General Hospi-
tal); Masanori Kawahara, MD PhD (Soshukai Okabe Clinic); Shigeru Aoki, MD (Sakanoue Family Clinic); Akira Demizu, MD (Demizu Clinic); Masahiro Goshima, MD, PhD
(Homecare Clinic Kobe); Keiji Goto, MD (Himawari Zaitaku Clinic); Yasuaki Gyoda, MD, PhD (Kanamecyo Home Care Clinic); Jun Hamano, MD (Division of Clinical
Medicine, Faculty of Medicine, University of Tsukuba); Kotaro Hashimoto, MD (Fukushima Home Palliative Care Clinic); Sen Otomo, MD (Shonan International Village
Clinic); Masako Sekimoto, MD (Sekimoto Clinic); Takemi Shibata, MD (Kanwakeakurinikku Eniwa); Yuka Sugimoto, MD (Sugimoto Homecare Clinic); Mikako Matsunaga,
MD (Senri Pain Clinic); Yukihiko Takeda, MD (Hidamari Clinic); Takeshi Sasara, MD (Yuuaikai Nanbu Hospital); and Jun Nagayama, MD (Peace Clinic Nakai).
DOI: 10.1002/cncr.29844, Received: October 22, 2015; Revised: November 23, 2015; Accepted: November 24, 2015, Published online March 28, 2016 in Wiley
Online Library (wileyonlinelibrary.com)
hazards analysis revealed that the place of death had a significant influence on the survival time in both unadjusted (hazard ratio
[HR], 0.86; 95% CI, 0.78-0.96; P < .01) and adjusted models (HR, 0.87; 95% CI, 0.77-0.97; P 5 .01). CONCLUSIONS: In comparison with
cancer patients who died in a hospital, cancer patients who died at home had similar or longer survival. Cancer 2016;122:1453-60.
C 2016 American Cancer Society.
V
KEYWORDS: advanced cancer patients, place of death, Prognosis in Palliative Care Study (PiPS) predictor model, survival time, type
of palliative care.
Age, mean 6 standard deviation, y 69.4 6 12.6 68.5 6 12.5 72.3 6 12.6
Male sex, No. (%) 1207 (58.3) 912 (56.8) 295 (63.9)
Site of primary cancer, No. (%)
Lung 434 (21.0) 338 (21.0) 96 (20.8)
Gastrointestinal 989 (47.8) 753 (46.9) 236 (51.1)
rationale for using the modified PiPS-A as the principal ent if the score was >3 points (scoring was performed by a
adjustment factor was that it was a superior predictor in physician without interviewing the patient).
comparison with other prediction scores investigated, We also recorded the demographic and clinical char-
including the Palliative Prognostic Score,20 the Delirium- acteristics of the participants, including the age, sex, place
Palliative Prognostic Score,21 and the Palliative Prognos- of palliative care, palliative performance scales,24 site of
tic Index.15,22 The modified PiPS-A includes the follow- the primary cancer and metastatic disease, anticancer ther-
ing: Abbreviated Mental Test score, pulse rate, anorexia, apy (including chemotherapy, hormone therapy, and
dyspnea, dysphasia, fatigue, weight loss during the last radiotherapy), presence of delirium (according to Diag-
month, Eastern Cooperative Oncology Group perform- nostic and Statistical Manual of Mental Disorders, 4th edi-
ance status, and global health status (which is rated on a tion25, and use of life-sustaining treatment (ie, parenteral
specific 7-point scale used in the original study: [1] hydration during the 48 to 72 hours before death and an-
extremely poor health to [7] normal health). Symptoms tibiotic therapy during the initial 3-week period after
were recorded as being either present or absent. Cognitive enrollment).
status was evaluated according to the Abbreviated Mental
Test score used in the original Prognosis in Palliative Care Statistical Analysis
Study models, as reported by Gwilliam et al.23 In the cur- Our main interest was the potential difference in the sur-
rent study, cognitive status was rated as absent if the score vival time between patients who died at home and patients
on the Abbreviated Mental Test was 3 points or as pres- who died in a hospital, so patients dying at home were
TABLE 2. Type of Palliative Care and Place of was followed by respiratory tract/intrathoracic cancer.
Death Among the 1582 patients who received hospital-based
Hospital Home palliative care, 1507 actually died in a hospital, and 75
Deaths, Deaths, Total, died at home, whereas among the 487 patients receiving
No. (%) No. (%) No. home-based palliative care, 100 died in a hospital, and
Hospital-based palliative 1507 (95.3) 75 (4.7) 1582
387 died at home (Table 2).
care service
Home-based palliative 100 (20.5) 387 (79.5) 487 Difference in the Survival Time Between
[95% CI, 0.82-1.02]; P 5 .108). The other significant The most important finding of this study is that
factors for survival time were age (per decade), sex, pallia- patients who died at home had a survival time similar to
tive performance scale category, lung cancer, gastrointesti- or significantly longer than that of patients who died in a
nal cancer, breast cancer, delirium, and modified PiPS-A hospital after adjustments for background factors with the
group (Table 3). proven prognostic classification Prognosis in Palliative
Care Study model. This finding is consistent with the
results of a preliminary study showing that patients receiv-
Differences in Life-Sustaining Treatment Before
Death ing home-based palliative care had significantly longer
The percentages of patients who received parenteral survival than those receiving hospital-based palliative care
hydration before death and received antibiotics were sig- with a median survival time of 67 days versus 33 days.14
nificantly higher among those who died in a hospital ver- Although that single-center study used only 5 factors for
sus those who died at home (Table 4). adjustments, the current multicenter study compared sur-
vival with a validated prognostic classification. To con-
firm whether the place of death influences the survival
DISCUSSION time, a randomized controlled trial is the most robust type
Findings of clinical research, but randomizing the place of death is
To the best of our knowledge, this is the first large-scale, practically impossible and unethical. Therefore, well-
prospective, multicenter study to explore the potential designed observational studies that compare survival by
association between the place of death and the survival matching patient background factors can provide the best
time. available evidence.
TABLE 3. Cox Proportional Hazards Analysis of the Survival Time and the Place of Death
Implications and Generalizations 13-29 days] for the hydration group vs 15 days [95% CI,
Our findings demonstrate that home death does not have 12-18 days] for the placebo group).26 Moreover, a previ-
a negative influence on the survival of cancer patients. ous prospective study revealed no significant difference in
Thus, the noninferiority of the survival time for patients the survival of cancer patients who received antimicrobial
dying at home suggests that an oncologist should not hesi- therapy versus patients who did not receive it (median sur-
tate to refer patients for home-based palliative care simply vival, 29 days for patients with antimicrobial therapy vs
because less medical treatment may be provided. 31 days for patients without antimicrobial therapy).27
Although patients with home deaths and home- Furthermore, this previous study found no significant dif-
based palliative care had similar or significantly longer ference in the survival of cancer patients with a diagnosed
survival in comparison with patients with hospital deaths infection versus patients without an infection (median
and hospital-based palliative care, it is interesting that life- survival, 29 days for patients with infections vs 31 days for
sustaining treatment (parenteral hydration and antibiot- patients without infections).27 These points need to be
ics) was provided for a significantly higher percentage of explored further in future studies.
patients with hospital deaths and hospital-based palliative
care. A possible reason for the finding that home death Strengths and Limitations
had no measurable negative influence on survival despite The strengths of this study were its large sample size, the
less use of parenteral hydration and antibiotics is that participation of institutions across the country, and the
these treatments were not effective for prolonging survival use of a valid prognostic classification system. The current
in the patient population of this study. This is consistent study also had some limitations. First, data on 63 patients
with the results of a previous randomized controlled (2.6%) were excluded because they had been lost to
study, which revealed that parenteral hydration had no follow-up or the date of death was missing. However, this
measurable effect on the survival of patients with proportion was small, and thus we believe that our conclu-
advanced cancer (median survival time, 21 days [95% CI, sions remain unaffected. Second, we could not adjust for
residual confounding primary predictors or the influence In conclusion, cancer patients who died at home had
on survival of unmeasured covariates (eg, symptom sever- similar or longer survival in comparison with those who
ity, disease progression, family support, availability of pal- died in a hospital.
liative care services, and patient and family preferences for
the place of death). Third, we recognize that patients who FUNDING SUPPORT
were referred for home-based palliative care might be This work was supported in part by the National Cancer Center
inherently different from those referred for hospital-based Research and Development Fund (25-A-22). All researchers were
care, although all known confounding factors were suc- independent of the funder.
cessfully adjusted. Finally, not all medical treatments were
recorded, and an exploration of the potential effect of the CONFLICT OF INTEREST DISCLOSURES
place of death on survival needs further investigation. The authors made no disclosures.
REFERENCES 15. Baba M, Maeda I, Morita T, et al. Survival prediction for advanced
cancer patients in the real world: a comparison of the Palliative
1. Miyashita M, Sanjo M, Morita T, Hirai K, Uchitomi Y. Good
Prognostic Score, Delirium-Palliative Prognostic Score, Palliative
death in cancer care: a nationwide quantitative study. Ann Oncol.
Prognostic Index and modified Prognosis in Palliative Care Study
2007;18:1090-1097.
predictor model. Eur J Cancer. 2015;51:1618-1629.
2. Wright AA, Keating NL, Balboni TA, Matulonis UA, Block SD,
Prigerson HG. Place of death: correlations with quality of life of 16. Baba M, Maeda I, Morita T, et al. Independent validation of the
patients with cancer and predictors of bereaved caregivers’ mental modified Prognosis Palliative Care Study (PiPS) predictor models in
health. J Clin Oncol. 2010;28:4457-4464. three palliative care settings. J Pain Symptom Manage. 2015;5:853-
3. Higginson IJ, Sen-Gupta GJ. Place of care in advanced cancer: a 860.
qualitative systematic literature review of patient preferences. 17. Hamano J, Morita T, Ozawa T, et al. Validation of the simplified
Palliative Prognostic Index using a single item from the Communi-